2025-03-12 10:48:36
Latest Post
W S Industries India Ltd's subsidiary to acquire 54.89 acres land for Rs. 46.66 crores
IKS Health wins Top Honors in 2025 Black Book Survey in New AI-Driven RCM Category
Mipco Seamless Rings Gujarat Ltd approves shifting of registered office
Crizac Limited gets Sebi Nod for Rs 1,000 cr IPO
REC Limited inaugurates REC Experience Center
Stock Report
Tatva Chintan Pharma Chem Ltd consolidated Q4 FY2023-24 net profit at Rs. 9.61 crores
Posted On : 2024-05-04 22:34:27( TIMEZONE : IST )
Tatva Chintan Pharma Chem Ltd has reported Consolidated financial results for the period ended March 31, 2024.
Financial Results (Q4 FY2024) - QoQ Comparison
The company has reported total income of Rs. 102.794 crores during the period ended March 31, 2024 as compared to Rs. 85.416 crores during the period ended December 31, 2023.
The company has posted net profit / (loss) of Rs. 9.614 crores for the period ended March 31, 2024 as against net profit / (loss) of Rs. 3.455 crores for the period ended December 31, 2023.
The company has reported EPS of Rs. 4.11 for the period ended March 31, 2024 as compared to Rs. 1.48 for the period ended December 31, 2023.
| Financials | Q4 FY2024 | Q3 FY2024 | % Change |
| Total Income | ₹ 102.794 crs | ₹85.416 crs |  20.35% |
| Net Profit | ₹9.614 crs | ₹3.455 crs | 178.26% |
| EPS | ₹4.11 | ₹1.48 | 177.70% |
Financial Results (Q4 FY2024) - YoY Comparison
The company has reported total income of Rs. 102.794 crores during the period ended March 31, 2024 as compared to Rs.125.356 crores during the period ended March 31, 2023.
The company has posted net profit / (loss) of Rs.9.614 crores for the period ended March 31, 2024 as against net profit / (loss) of Rs.16.954 crores for the period ended March 31, 2023.
The company has reported EPS of Rs.4.11 for the period ended March 31, 2024 as compared to Rs.7.65 for the period ended March 31, 2023.
| Financials | Q4 FY2024 | Q4 FY2023 | % Change |
| Total Income | ₹ 102.794 crs | ₹125.356 crs |  -18.00% |
| Net Profit | ₹9.614 crs | ₹16.954 crs | -43.29% |
| EPS | ₹4.11 | ₹7.65 | -46.27% |
Financial Results (Year Ended FY2024) - YoY Comparison
The company has reported total income of Rs.401.013 crores during the Financial Year ended March 31, 2024 as compared to Rs.429.356 crores during the Financial Year ended March 31, 2023.
The company has posted net profit / (loss) of Rs.30.354 crores for the Financial Year ended March 31, 2024 as against net profit / (loss) of Rs.45.487 crores for the Financial Year ended March 31, 2023.
The company has reported EPS of Rs.13.26 for the Financial Year ended March 31, 2024 as compared to Rs.20.52 for the Financial Year ended March 31, 2023.
| Financials | Year Ended FY2024 | Year Ended FY2023 | % Change |
| Total Income | ₹401.013 crs | ₹429.356 crs | -6.60% |
| Net Profit | ₹30.354 crs | ₹45.487 crs | -33.27% |
| EPS | ₹13.26 | ₹20.52 | -35.38% |
Shares of Tatva Chintan Pharma Chem Ltd was last trading in BSE at Rs. 1245.55 as compared to the previous close of Rs. 1227.00. The total number of shares traded during the day was 839 in over 170 trades.
The stock hit an intraday high of Rs. 1255.90 and intraday low of 1226.75. The net turnover during the day was Rs. 1040221.00.
